UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
Pursuant
to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For the
month of April 2009
Commission
File Number: 0-29350
Vasogen
Inc.
(Translation
of registrant’s name into English)
4
Robert Speck Parkway, 15
th
Floor,
Mississauga, Ontario, L4Z 1S1
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1). _____
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K
if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): _____
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant's "home country"), or under the rules of the home country exchange on
which the registrant's securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant's security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If
“Yes” is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
.
Consolidated Financial Statements
and Notes to Interim Financial Statements for the period ended February 28, 2009
are attached as exhibit 99.1 to this report and are incorporated herein by
reference.
Management’s Discussion and Analysis
for the period ended February 28, 2009 is attached as Exhibit 99.2 to this
report and is incorporated herein by reference. Forms 52-109F2 Certification of
Interim Filings are attached as exhibit 99.3 to this report and are incorporated
herein by reference.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
VASOGEN
INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/
Graham Neil
|
|
Name:
|
Graham
Neil
|
|
Title:
|
Vice-President,
Finance and
|
|
|
Chief
Financial Officer
|
Date: April
13, 2009
EXHIBIT
LIST
Exhibit
|
|
Description
|
|
|
|
99.1
|
|
Financial
Statements and Notes to Consolidated Financial Statements for the period
ended February 28, 2009
|
99.2
|
|
Management’s
Discussion and Analysis for the period ended February 28,
2009
|
99.3
|
|
Forms
52-109F2 CEO/CFO Certification of Interim
Filings
|